NASDAQ : ALT
Altimmune, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 2.04 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 396.82M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.
Details
| Name | Altimmune, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 57 |
| Founded | 1997 |
| Ceo | Jerome Durso |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US02155H2004 |
| Cusip | 02155H200 |
| Cik | 0001326190 |
| Sic | 2834 |
Key executives
| Name | Title |
|---|---|
| Jerome Benedict Durso | Chairman, Chief Executive Officer and President |
| Dr. M. Scot Roberts Ph.D. | Chief Scientific Officer |
| Dr. Christophe Arbet-Engels M.B.A., M.D., Ph.D. | Chief Medical Officer |
| Gregory L. Weaver CPA, M.B.A. | Chief Financial Officer |
| Richard Menziuso | Vice President, Global Controller and Principal Accounting Officer |
| Bertrand Georges Ph.D. | Chief Technology Officer |
| Luis Sanay C.F.A. | Vice President of Investor Relations |
| Tony Blandin B.S. | Vice President of Quality and Compliance Management |
| Robin E. Abrams J.D. | Chief Legal Officer and Corporate Secretary |
| Raymond M. Jordt M.B.A., M.S. | Chief Business Officer |
Contact
| Address | 910 Clopper Road, Suite 201S, Gaithersburg, Maryland 20878, United States |
| Phone | 240 654 1450 |
| Website | https://altimmune.com |